An Important Step Forward in ITP: Shreeram Aradhye Shares Ianalumab Phase III Results!
Shreeram Aradhye, President, Development and Chief Medical Officer at Novartis, shared on LinkedIn:
”Today, at the Late-Breaking Abstract Session at the 67th American Society of Hematology Annual Meeting and Exposition, we shared positive results from a Phase III trial in adults with primary immune thrombocytopenia (ITP) previously treated with corticosteroids.
With a course of four once-monthly doses, our investigational therapy studied in this trial offers a promising alternative to chronic treatment.
ITP is a rare autoimmune condition where the immune system mistakenly destroys platelets, leading to prolonged bleeding, easy bruising and chronic fatigue.
This potential treatment is designed to target B cells, a key driver in ITP and other autoimmune diseases, through a dual mechanism of action.
Today’s results represent an important step forward in ITP and add to the growing body of evidence for this therapy, which is currently being studied across multiple B cell-driven conditions.
Thank you to all the patients, investigators, and teams involved in this research.”
Stay updated on all scientific advances with Hemostasis Today.
-
May 6, 2026, 02:58Limiaa Babikir: What Is Polyspecific DAT?
-
May 6, 2026, 02:47Karen Rollinson: Grateful to Be Connecting with so Many Families and Advocates at HFA 2026 in New Orleans
-
May 6, 2026, 02:38Moustafa Abdou: Is the Bone Marrow Examination Still the ‘Gold Standard’?
-
May 6, 2026, 02:23Khaled Musallam: When the Worlds of Thalassemia and Hemophilia Converge
-
May 6, 2026, 02:12Caitlin Raymond: How STOP-BABESIOSIS Just Rewrote 40 Years of Practice
-
May 5, 2026, 16:28Nikolay Novitski: A New Era in Cardiovascular Prevention
-
May 5, 2026, 16:23Satyam Arora: Best Abstract Award in Pediatric Apheresis at ASFA 2026 Congress
-
May 5, 2026, 16:17Hannah Omunakwe: Your Sick Child Has a Clot. Did You See That Coming?
-
May 5, 2026, 15:57Venous Thromboembolism Risk in Pregnancy and the Postpartum Period – NBCA